Category: imidazoles-derivatives

TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia was written by Lazarian, Gregory;Theves, Floriane;Hormi, Myriam;Letestu, Remi;Eclache, Virginie;Bidet, Audrey;Cornillet-Lefebvre, Pascale;Davi, Frederic;Delabesse, Eric;Estienne, Marie-Helene;Etancelin, Pascaline;Kosmider, Olivier;Laibe, Sophy;Lode, Laurence;Muller, Marc;Nadal, Nathalie;Naguib, Dina;Pastoret, Cedric;Poulain, Stephanie;Sujobert, Pierre;Veronese, Lauren;Imache, Samia;Lefebvre, Valerie;Cymbalista, Florence;Baran-Marszak, Fanny;Soussi, Thierry;French Innovative Leukemia Organisation. And the article was included in American Journal of Hematology in 2022.Synthetic Route of C16H21Cl2N3O2 The following contents are mentioned in the article:

TP53 aberrations, including somatic mutations of TP53 gene and 17p deletion, are a major predictive factor of resistance to fludarabine based chemotherapy in chronic lymphocytic leukemia (CLL) and remain an adverse prognostic factor in the chemofree era. TP53 mutations typically occur all along the DNA-binding domain of the p53 protein. In this study, we aimed at characterizing the profile of the TP53 variants in CLL, their distributions, and a correlation with clin. data. To this end, we retrospectively analyzed a large collection of 568 CLL-associated TP53 variants in 336 patients compiled from centers affiliated with the French Innovative Leukemia. Organization-CLL. Fluorescence in situ hybridization anal. for del(17p) status was available for 207 patients, of which 108 (52%) harbored a 17p deletion. Based on the IGHV mutation status, most patients belong to a high risk group as 73% (172/236) were IGHV unmutated. In the present study, CLL patients frequently harbored multiple subclones with different TP53 mutations. Interestingly, while mutations at classical TP53 hot spot positions (codons 175, 248, or 273) were observed both as single and associated mutations, we noticed that variants at codon 234 were found mostly in polymutated patients (82% cases), highlighting an important intratumoral heterogeneity in cases harboring this mutation. However, in contrast to the other hot spot mutations such as those at codon 175 or 248, the absence of variants at position 234 in any of the untreated patients in our database. Strongly supports the possibility that this mutation is associated with the mutagenic effect of CLB. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Synthetic Route of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Synthetic Route of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A thermodynamic framework for determination of gas hydrate stability conditions and water activity in ionic liquid aqueous solution was written by Rasoolzadeh, Ali;Bakhtyari, Ali;Sedghamiz, Mohammad Reza;Javanmardi, Jafar;Nasrifar, Khashayar;Mohammadi, Amir H.. And the article was included in Journal of Molecular Liquids in 2022.Synthetic Route of C10H20N2O4S The following contents are mentioned in the article:

The formation of gas hydrates in pipelines and plugging of the gas flow path are a major cause of operating expenses, safety issues, pressure drop, and fatal accidents. Therefore, the inhibition of gas hydrate formation is of paramount importance. The utilization of a new class of inhibitors such as ionic liquids (ILs) is currently of great interest. In this regard, adjusting water activity in the inhibitor blend (water + IL) is a vital factor. Several models have been developed to calculate the activity of water in the presence of IL(s). The major disadvantage of these models is their correlative basis. This study aimed to propose a rigorous predictive model for the calculation of water activity in the presence of IL(s), which would then be applied in the prediction of the gas hydrate stability conditions. The model is made up of a mol. term (the short-range interactions from Free-Volume-Flory-Huggins (FVFH) activity model) as well as a contribution from ionic interactions as a result of IL(s) dissociation in water (the long-range electrostatic interactions from the extended Debye-Huckel (EDH) model). The overall absolute temperature deviation and the average absolute relative deviation percent in the calculated gas (methane and carbon dioxide) hydrate dissociation temperatures for the whole databank (500 data points including 37 ILs) were found to be 0.61 K and 0.22%, resp. This proves the superiority of the model over the previous correlative-basis ones. Finally, it is concluded that the higher temperature, the higher the IL(s) concentration, and the lower IL(s) mol. weight(s) result in larger model deviations. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Synthetic Route of C10H20N2O4S).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Synthetic Route of C10H20N2O4S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma was written by Alderuccio, Juan Pablo;Arcaini, Luca;Watkins, Marcus P.;Beaven, Anne W.;Shouse, Geoffrey;Epperla, Narendranath;Spina, Michele;Stefanovic, Alexandra;Sandoval-Sus, Jose;Torka, Pallawi;Alpert, Ash B.;Olszewski, Adam J.;Kim, Seo-Hyun;Hess, Brian;Gaballa, Sameh;Ayyappan, Sabarish;Castillo, Jorge J.;Argnani, Lisa;Voorhees, Timothy J.;Saba, Raya;Chowdhury, Sayan Mullick;Vargas, Fernando;Reis, Isildinha M.;Kwon, Deukwoo;Alexander, Jonathan S.;Zhao, Wei;Edwards, Dali;Martin, Peter;Cencini, Emanuele;Kamdar, Manali;Link, Brian K.;Logothetis, Constantine N.;Herrera, Alex F.;Friedberg, Jonathan W.;Kahl, Brad S.;Luminari, Stefano;Zinzani, Pier Luigi;Lossos, Izidore S.. And the article was included in Blood Advances in 2022.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:

Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin lymphoma. No consensus exists regarding the standard-of-care in patients with advanced-stage disease. Current recommendations are largely adapted from follicular lymphoma, for which bendamustine with rituximab (BR) is an established approach. We analyzed the safety and efficacy of frontline BR in EMZL using a large international consortium. We included 237 patients with a median age of 63 years (range, 21-85). Most patients presented with Eastern Cooperative Oncol. Group (ECOG) performance status 0 to 1 (n = 228; 96.2), stage III/IV (n = 179; 75.5), and intermediate (49.8) or high (33.3) Mucosa Associated Lymphoid Tissue International Prognosis Index (MALT-IPI). Patients received a median of 6 (range, 1-8) cycles of BR, and 20.3(n = 48) received rituximab maintenance. Thirteen percent experienced infectious complications during BR therapy; herpes zoster (4) was the most common. Overall response rate was 93.2with 81complete responses. Estimated 5-yr progression-free survival (PFS) and overall survival (OS) were 80.5(95CI, 73.1to 86) and 89.6(95CI, 83.1to 93.6), resp. MALT-IPI failed to predict outcomes. In the multivariable model, the presence of B symptoms was associated with shorter PFS. Rituximab maintenance was associated with longer PFS (hazard ratio = 0.16; 95CI, 0.04-0.71; P = .016) but did not impact OS. BR is a highly effective upfront regimen in EMZL, providing durable remissions and overcoming known adverse prognosis factors. This regimen is associated with occurrence of herpes zoster; thus, prophylactic treatment may be considered. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Electric Literature of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Rational design and construction of a serious of highly water-stable coordination polymers with various N,N’-donor linkers: Syntheses, diversity structures, and dye adsorption property was written by Fan, Chuanbin;Xu, Cungang;Zong, Ziao;Zhang, Xiaoyin;Zhu, Bin;Wang, Lulu;Zhang, Xia;Bi, Shuangyu;Fan, Yuhua. And the article was included in Journal of Solid State Chemistry in 2020.Electric Literature of C11H9N5 The following contents are mentioned in the article:

In this study, authors have synthesized six new coordination polymers (CPs), namely {[Cu₆(3,5-bip)₆(H₂O)₁₂(SO₄)₆]·3H₂O}_n (1), [Co(3,5-bip)(H₂O)₃(SO₄)]_n (2), {[Cu(1,3-bit)₂(H₂O)₂]·2(NO₃)}_n (3), {[Cu₂(1,3-bit)₂(1,3-bcbb)₂]·4(H₂O)}_n (4), [Cu(4,4′-bibp) (H₂O)(NO₃)₂]_n (5), [Cu(4,4′-bibp)(4,4′-Hsbdc)]_n (6) via solvothermal methods. The structures of these new CPs have been characterized by elemental anal., FTIR, TG anal., PXRD and single crystal x-ray diffraction techniques. Meanwhile, the title CPs are explored for adsorption of organic dyes, i.e., anionic dyes (congo red (CR), and methyl orange (MO)) and cationic dye (methylene blue (MB)) considered extensively as water colorants pollutants. Worth noting, complex 3 can adsorb anionic dyes (CR and MO) quickly; complex 6 shows great performance in CR adsorption. Kinetic study reveals that the adsorption process is performed via pseudo-second-order reaction. The dye removal investigations of complexes 3 and 6 support that ions exchange and H-bonding interactions between CPs and target organic dyes are significant factors, heavily affecting dye adsorption. They have excellent potential in wastewater treatment. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Electric Literature of C11H9N5).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Electric Literature of C11H9N5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study. was written by Bang, Chang Seok;Shin, Woon Geon;Seo, Seung In;Choi, Min Ho;Jang, Hyun Joo;Park, Se Woo;Kae, Sea Hyub;Yang, Young Joo;Shin, Suk Pyo;Baik, Gwang Ho;Kim, Hak Yang. And the article was included in Surgical endoscopy in 2019.COA of Formula: C18H20N3NaO3S The following contents are mentioned in the article:

BACKGROUND: The optimal treatment regimen or the duration of treatment for an endoscopic submucosal dissection (ESD)-induced gastric ulcer has not been established. The aim of this study was to assess the efficacy of novel proton-pump inhibitor, ilaprazole, for the treatment of ESD-induced gastric ulcer. METHODS: This was a prospective, open-label, randomized multicenter study. Between June 2015 and March 2018, a total of 176 patients (178 lesions) who underwent ESD for a gastric neoplasm were randomly allocated to receive the oral proton-pump inhibitor ilaprazole 20 mg or rabeprazole 20 mg daily for 8 weeks. The primary outcome was the ulcer healing rate at 4 and 8 weeks. RESULTS: A total of 155 (157 lesions) and 154 patients (156 lesions) were included in the modified intention-to-treat (mITT) and per-protocol analyses, respectively. There was no significant difference in the ulcer healing rate (ilaprazole vs. rabeprazole, 97.4% vs. 97.0 p = 0.78 at 4 weeks, 100% vs. 100%, p = 0.95 at 8 weeks in the mITT analysis) or stage of ulcer (scar stage, 25.6% vs. 17.7%, p = 0.25 at 4 weeks, 92.3% vs. 88.6%, p = 0.59 at 8 weeks in the mITT analysis) between the treatment groups. The quality of ulcer healing was not significantly different between the two groups. No independent predictive factor for higher-quality ulcer healing was found in the multivariate analysis. CONCLUSIONS: According to this trial, ilaprazole and rabeprazole showed no significant difference in the healing of artificial gastric ulcers. Most of the ulcers achieved complete healing within 4-8 weeks. TRIAL REGISTRATION: ClinicalTrial.gov NCT02638584. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6COA of Formula: C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.COA of Formula: C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Design, development and optimization of orodispersible tablets of rabeprazole sodium by direct compression method using different concentrations of synthetic super-disintegrants was written by Bhatti, Musharraf Abbas;Afzal, Muhammad;Bhatti, Muhammad Abbas;Tariq, Fatima. And the article was included in World Journal of Pharmacy and Pharmaceutical Sciences in 2020.Formula: C18H20N3NaO3S The following contents are mentioned in the article:

Improved bioavailability, rapid onset of action due to rapid systemic absorption and enhanced patient compliance in patients suffering from certain diseases such as peptic/duodenal ulcer, gastro-esophageal reflux disease, ulcers induced by NSAIDs or Zollinger-Ellison syndrome has increased the demand of orodispersible tablets. In the present study, orordispersible tablets of Rabeprazole sodium has been prepared by using direct compression method, in which different concentration of synthetic super-disintegrants such as croscarmellose sodium, crospovidone and sodium starch glycolate ranging from 2% to 7% has been used to formulate such dosage form with rapid disintegration and improved dissolution in order to increase bioavailability. In this study, nine formulations has been prepared and evaluated by different physicochem. parameters such as pre-formulation studies such as compatibility studies by using Fourier transform Infraredspectroscopy, Differential scanning calorimetry anal., thermo-gravimetric anal. were used to determine degree of crystallinity of the drug, pre-compression evaluation of powder blend such as Angle of repose, Bulk d., Tapped d., Carr’s index and Hausner’s ratio were carried out to determine the flow properties. After the formulation of tablets, post-compression studies were carried out for the evaluation of orodispersible tablets including the evaluation of hardness, thickness, diameter, friability, weight variation, content niformity and stability studies. It is concluded that all the formulations have a disintegration time within official limits, but formulation T6 was an optimized dosage form having average disintegration time of 1.6 s that releases upto 102.15% drug in 15min. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Formula: C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Formula: C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study was written by Falhammar, Henrik;Lindh, Jonatan D.;Calissendorff, Jan;Skov, Jakob;Nathanson, David;Mannheimer, Buster. And the article was included in European Journal of Internal Medicine in 2019.Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Background: Small observational studies and case reports have indicated that proton pump inhibitors (PPIs) may cause hyponatremia. Whether there is a difference between the individual PPIs is yet unknown. Since PPIs are one of the most commonly prescribed groups of drugs, even a rare adverse reaction may have large implications. The objective was to study the association between PPIs and hospitalization due to hyponatremia. Methods: This register-based case-control study was based on the general Swedish population. Patients hospitalized with a principal diagnosis of hyponatremia (n = 14,359) were compared to matched controls (n = 57,383). The association between newly initiated (≤90 days) and ongoing PPI use was explored using multivariable logistic regression adjusting for concomitant drugs, medical conditions, previous hospitalizations and socioeconomic factors. Results: Adjusted ORs (95%CI) for hospitalization due to hyponatremia, compared to controls, were for newly initiated: omeprazole 2.67 (2.37-3.01); pantoprazole 2.06 (1.32-3.19); lansoprazole 1.19 (0.72-1.94); esomeprazole 2.89 (2.21-3.79) and any PPI 2.78 (2.48-3.11). Only one individual had been newly initiated on rabeprazole and had been hospitalized due to hyponatremia. Adjusted ORs (95%CI) for individuals with ongoing treatment were for: omeprazole 1.04 (0.97-1.11); pantoprazole 0.81 (0.62-1.05); lansoprazole 0.90 (0.70-1.15); rabeprazole 3.34 (0.84-11.43); esomeprazole 1.12 (0.94-1.33) and any PPI 1.04 (0.98-1.11). Conclusions: With the exception of lansoprazole, this study suggests an association between any newly initiated PPI-treatment and hospitalization due to hyponatremia. Ongoing PPI use was not associated with an increased risk. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia-A British Society for Haematology guideline was written by Pratt, Guy;El-Sharkawi, Dima;Kothari, Jaimal;D’Sa, Shirley;Auer, Rebecca;McCarthy, Helen;Krishna, Rajesh;Miles, Oliver;Kyriakou, Charalampia;Owen, Roger. And the article was included in British Journal of Haematology in 2022.Computed Properties of C16H21Cl2N3O2 The following contents are mentioned in the article:

A review. The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with Waldenstrom macroglobulinemia. In individual patients, circumstances may dictate an alternative approach. This guideline was compiled according to the British Society for Haematol. (BSH) process at . Recommendations are based on a review of the literature using Medline, Pubmed, Embase, Central, Web of Science searches from beginning of 2013 (since the publication of the previous guidelines) up to Nov. 2021. The following search terms were used: Waldenstrom(‘s) macroglobulin(a)emia OR lymphoplasmacytic lymphoma, IgM(-related) neuropathy OR cold h(a)emagglutinin disease OR cold agglutinin disease OR cryoglobulin(a)emia AND (for group a only) cytogenetic OR mol. OR mutation OR MYD88 OR CXCR4, management OR treatment OR transfusion OR supportive care OR plasma exchange OR plasmapheresis OR chemotherapy OR bendamustine OR bortezomib OR ibrutinib OR fludarabine OR dexamethasone OR cyclophosphamide OR rituximab OR everolimus, bone marrow transplantation OR stem cell transplantation. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at . Review of the manuscript was performed by the British Society for Haematol. (BSH) Guidelines Committee Haemato-Oncol. Task Force, the BSH Guidelines Committee and the Haemato-Oncol. sounding board of BSH. It was also on the members section of the BSH website for comment. It has also been reviewed by UK Charity WMUK; these organisations do not necessarily approve or endorse the contents. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Computed Properties of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Computed Properties of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Multicenter, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of a Controlled-release, Once-daily UIC201609/UIC201610 Combination Therapy for Functional Dyspepsia: Preliminary Study. was written by Lee, Jung Won;Youn, Young Hoon;Choi, Suck Chei;Lee, Kwang Jae;Kim, Nayoung. And the article was included in The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi in 2021.Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Backgrounds/Aims: Functional dyspepsia is a disease involving a range of upper gastrointestinal symptoms derived from various pathophysiologies. Tablets containing a combination of rabeprazole and controlled-release (CR) mosapride were recently developed. To investigate a more effective treatment, this trial evaluated the efficacy and safety of UIC201609/UIC201610 as a preliminary study. Methods: A multicenter, double-blind, randomized study was performed on 30 subjects. UIC201609/UIC201610 (combination of rabeprazole and CR mosapride) was the case group, and the two control groups were rabeprazole 10 mg once a day and mosapride 15 mg CR tablet once a day. As a primary efficacy endpoint of the study, the changes in the total score of eight items of the Nepean Dyspepsia Index-Korean version were analyzed at 2 weeks and 4 weeks. The outcomes regarding safety were collected. Results: The total symptom score of Nepean Dyspepsia Index-Korean decreased in the rabeprazole single group (29.4±17.1), mosapride CR single group (33.4±15.6), and UIC201609/UIC201610 group (33.4±11.8) at 4 weeks without significant differences. On the other hand, the UIC201609/UIC201610 combination group showed more score reduction of pain in the upper abdomen, burning in the upper abdomen compared to each control group, but it did not reach statistical significance. No difference was found in safety analysis. Conclusions: UIC201609/UIC201610 once daily showed some improvement in epigastric pain and dyspepsia in patients with functional dyspepsia, but there was no significance. Further study based on the advanced clinical trial design will be needed to confirm the efficacy of UIC201609/UIC201610 combination therapy in the future. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Recommanded Product: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Nine-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant was written by Khouri, Issa F.;Milton, Denai R.;Gulbis, Alison M.;Jabbour, Elias J.;Nastoupil, Loretta;Ledesma, Celina;Anderlini, Paolo;Bashir, Qaiser;Daher, May;Im, Jin S.;Iyer, Swaminathan P.;Marin, David;Mehta, Rohtesh S.;Olson, Amanda L.;Popat, Uday R.;Qazilbash, Muzaffar;Saini, Neeraj;Samaniego, Felipe;Rondon, Gabriela;Medeiros, Jeffrey L.;Champlin, Richard E.. And the article was included in Clinical Cancer Research in 2021.Recommanded Product: 16506-27-7 The following contents are mentioned in the article:

To compare outcomes between patients with relapsed follicular lymphoma who received a nonmyeloablative allogeneic stem cell transplant (alloSCT) and those who received an autologous transplant (autoSCT). We evaluated 194 patients with follicular lymphoma who received an alloSCT (n = 98) or autoSCT (n = 96) at MD Anderson Cancer Center (Houston, TX). The transplant type used was based on donor availability and by Medicare reimbursement guidelines. Patients who received an alloSCT were enrolled in four consecutive trials in which they received Hudarabine1 cyclophosphamide (or bendamustine), and rituximab conditioning. autoSCT patients received R-BEAM (rituximab, carmustine, etoposide, cytarabine, and mclphalan). The median follow-up of survivors was 108 mo for the alloSCT group and 102 mo for the autoSCT group. Overall survival was significantly better for patients who received an alloSCT compared with those who received an autoSCT (62% vs. 46%; P = 0.048). Similarly, progression-free survival rates were 52% in patients who received an alloSCT and 31% in those who received an autoSCT (P < 0.001), and the 8-yr relapse rates were 11% and 43%, resp. (P < 0.0001). Only three patients in the alloSCT group relapsed beyond 3.5 years. In the alloSCT group, the rates for grade 2 to 4 acute graft-versushost disease (GVHD)1 grade 3 to 4 acute GVHD1 and extensive chronic GVHD were 22%, 9%, and 38%, resp. In the autoSCT group, the 8-yr incidence of secondary myelodysplasia was 11%. Nonrelapse mortality was similar between the two groups (15% vs. 11% at 8 years; P = 0.27). This study shows that alloSCT is curative and confers superior survival compared with autoSCT in patients with follicular lymphoma. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Recommanded Product: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem